A recent study has revealed that women face serious adverse effects from chemical abortions at a rate that is 22 times higher than what the FDA and manufacturers disclose. This calls for federal intervention, as leaving the responsibility to states is insufficient for safeguarding women.
If these drugs pose such risks, major pharmaceutical companies should not be allowed to conceal this information from women.
The study, conducted by the Center for Ethics and Public Policy, represents the most extensive analysis of the impacts of commonly used chemical abortion drugs, examining 330 million patients and over 850,000 claims related to Mifepristone since 2017.
Data Discrepancies
While the FDA and manufacturers claim that serious side effects occur in just 0.5% of cases, actual patient claims show a significantly higher incidence. One in nine women reportedly experiences life-threatening conditions like sepsis or severe bleeding within 45 days of taking these drugs.
The Guttmacher Institute, associated with Planned Parenthood, indicates that nearly two-thirds of abortions in the U.S. are chemical, suggesting that hundreds of thousands of women have dealt with serious complications in the last decade—definitely not “rare” or “safe”.
Additionally, federal safety claims are based on small and outdated studies from over 40 years ago, according to the EPPC.
Under real-world conditions, it appears abortion drugs can be extremely dangerous. Another EPPC study noted about 10.93% of women suffered significant harm from these medications. It raises the question: which other FDA-approved drugs can remain available with such a high rate of serious adverse events?
A Lack of Safe Conditions
Given this alarming data, the federal government can no longer justify relaxing the monitoring protocols for abortion drugs. Necessary safety measures, like mandatory doctor oversight and adverse event reporting, have been removed under both the Obama and Biden administrations. These protections should be reinstated and thoroughly reevaluated in terms of drug safety and FDA approval.
This is not merely a “state issue.” Abortion medications are often distributed across state lines without necessary doctor involvement. States with strict abortion regulations shouldn’t be sending these risky drugs to places like Texas, which has implemented protective measures for women and their babies.
Our representatives in Washington cannot use federalism as an excuse for inaction on this issue. If abortion drugs are actively circulated nationwide, then women’s safety remains in jeopardy, regardless of what state legislation exists.
Women Have the Right to Know
No matter where you stand on the topic, there should be agreement that if these drugs are risky, large pharmaceutical companies must be held accountable for disclosing that information to women. The FDA needs to confront this issue rather than ignore or cover it up.
A letter has been sent to President Trump, urging him to take appropriate action. The letter, supported by many pro-family advocates, calls for a full investigation into mifepristone. It emphasizes that reinstating original safety protocols is essential for the lives of women and fetuses.
Furthermore, in Iowa, where the first Presidential Caucus occurs, there is a commitment to shielding women from the dangers of Mifepristone. Candidates pursuing the presidency should be asked where they stand on protecting women’s rights as a federal issue.
